Despite the common clinical use of numerous active cytotoxic agents for breast cancer therapy, and the combinations that are derived from them, the median survival for patients with metastatic breast cancer has not been dramatically improved over the past two decades. Furthermore, when the expected outcome of treatment is not cure, optimizing the dynamic equilibrium between chemotherapy-induced side effects and the benefits attributable to chemotherapy-mediated relief of cancer-related symptomatology becomes paramount. The search for active agents to this end has recently included the clinical evaluation of the novel nucleoside analogue gemcitabine (2′,2′-difluorodeoxycytidine). This review summarizes the recent and current development of this agent.

Keywords:
Gemcitabine, Chemotherapy, Breast cancer, Phase II studies, 2′,2′-difluorodeoxycytidine
1.
Pritchard KI: Endocrine therapy of breast cancer. Oncology 2000;14:483–492.
2.
Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785–1791.
3.
Seidman AD, Gollamudi S: Combining chemotherapy and radiotherapy for metastatic breast cancer: Opportunities and obstacles. Adv Oncol 1998;14:25–29.
4.
D’Andrea G, Seidman AD: Docetaxel and paclitaxel in breast cancer therapy: Present status and future prospects. Semin Oncol 1997;24(4 suppl 13):S13-27–S13-44.
5.
Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688–2699.
6.
Seidman AD, Hudis CA, Albanell J, et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353–3361.
7.
Nabholtz JM, Falkson G, Campos D, et al: A phase III trial comparing doxorubicin (A) and docetaxel (T) to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for MBC (abstract No. 485). Proc Am Soc Clin Oncol 1999;18:127a.
8.
Seidman AD, Tiersten A, Hudis C, et al: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575–2581.
9.
Sparano JA: Taxanes for breast cancer: An evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer 2000;1:32–40.
10.
Munster P, Seidman AD: Management of metastatic breast cancer: Reasons for optimism. Oncology Special Edition 1999;2:101–104.
11.
Sledge GW, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin vs. paclitaxel vs. doxorubicin + paclitaxel as first line therapy for metastatic breast cancer: An intergroup trial (abstract No. 2). Proc Am Soc Clin Oncol 1997;16:1a.
12.
Nabholtz JM, Senn JH, Bezwoda WR, et al: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing therapy. J Clin Oncol 1999;17:1413–1424.
13.
Bishop J, Dewar J, Toner GC, et al: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999;17:2355–2364.
14.
Joensuu H, Holli K, Heikkinen M, et al: Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial. J Clin Oncol 1998;16:3720–3730.
15.
Heidemann H, Stoeger H, Souchon R, et al: Balance of time to progression, quality of life, and overall survival: More gain from treatment in single agent treatment with mitoxantrone (N) than with the combination of fluorouracil, epirubicin, cyclophosphamide (FEC) Results of a multicenter randomized trial in high risk metastatic breast cancer (abstract No. 284). Proc Am Soc Clin Oncol 2000;19:74a.
16.
Norton L, Slamon D, Leyland-Jones B, et al: Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER-2+) metastatic breast cancer (MBC) (abstract No. 483). Proc Am Soc Clin Oncol 1999;18:127a.
17.
O’Shaugnessy J: Capecitabine in combination with docetaxel: Clinical studies in patients with metastatic breast cancer (abstract No. 45). Proc Chemotherapy Foundation Symposium XVIII:52, 2000.
18.
Fossati R, Confalonieri C, Torri V, et al: Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;16:3439–3460.
19.
Geels P, Eisenhauer E, Bezjak A, Zee B, Day A: Palliative effect of chemotherapy: Objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 2000;18:2395–2405.
20.
Huang I, Chubb S, Hertel LW, et al: Mechanism of action of 2′,2′-deoxycytidine triphosphate on DNA synthesis. Proc Am Assoc Cancer Res 1990;31:426.
21.
Hertel LW, Boder GB, Kroin JS, et al: Evaluation of the antitumor activity of gemcitabine (difluoro-2′-deoxycytidine). Cancer Res 1990;50:4417–4422.
22.
Abbruzzese JL, Grunewald R, Weeks EA, et al: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491–498.
23.
Anderson H, Lund B, Bach F, et al: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1994;12:1821–1826.
24.
Lund B, Hansen OP, Theilade K, et al: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer. J Natl Cancer Inst 1994;86:1530–1533.
25.
Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29–34.
26.
Carmichael J, Possinger K, Philip P, et al: Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 1995;13:2731–2736.
27.
Blackstein M, Vogel CL, Ambinder R, et al: Phase II study of gemcitabine in patients with metastatic breast cancer (abstract No. 135). Proc Am Soc Clin Oncol 1996;15:117.
28.
Spielmann M, Kalla S, Llombart-Cussac A, et al: Activity of gemcitabine in metastatic breast cancer patients previously treated with anthracycline containing regimens. Eur J Cancer 1997;33(suppl 8):A663.
29.
Possinger K, Kaufmann M, Coleman R, et al: Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 1999;10:155–162.
30.
Fram RJ, Rochibaud N, Bishov SD, et al: Interactions of cis-diamminedichloroplatinum (II) with 1-beta-D-arabinofuranosylcytosine in LoVo colon carcinoma cells. Cancer Res 1987;47:3360–3365.
31.
Bergman AM, Ruiz van Helperen VWT, Veerman G, et al: Synergistic interactions between cisplatin and gemcitabine in ovarian and colon cancer cell lines; in Sahota A, Taylor M (eds): Purine and Pyrimidine Metabolism in Man VIII. New York, Plenum, 1995, pp 139–143.
32.
Nagourney RA, Link JS, Blitzer JB, et al: Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 2000;18:2245–2249.
33.
Doroshow JH, Tetef M, Margolin K, et al: Significant activity of gemcitabine (Gem) and cisplatin (Ddp) in both heavily (H) and minimally (M)-pretreated metastatic breast cancer (Mbc) patients (Pts): A California Cancer Consortium/Loyola University Chicago Trial (abstract No. 609H). Proc Am Soc Clin Oncol 2000;19:155a.
34.
Burch PA, Maillard JA, Hillman DW, et al: Phase II study of gemcitabine and cisplatin in patients with metastatic breast cancer and failure on prior chemotherapy: A North Central Cancer Treatment Group Trial (abstract No. 322). Breast Cancer Res Treat 2000;64:81.
35.
Galvez CA, Galmarini F, Curie M, et al: Monthly cisplatin and gemcitabine as second line chemotherapy for patients with advanced breast cancer (abstract No. 324). Breast Cancer Res Treat 2000;64:81.
36.
Tagliabue P, Mariani G, Brambilla C, et al: Dose-finding study of gemcitabine (G) plus vinorelbine (V) in metastatic breast cancer (MBC) (abstract No. 423). Proc Am Soc Clin Oncol 1999;18:112a.
37.
Gokmen E, Karabulut B, Sezgin C, et al: A phase II study of gemcitabine (G) and vinorelbine (V) in patients with advanced breast cancer (ABC) (abstract No. 427). Proc Am Soc Clin Oncol 1999;19:110a.
38.
Perez-Manga G, Lluch A, Alba E, et al: Gemcitabine in combination with doxorubicin in advanced breast cancer: Final results of a phase II pharmacokinetic trial. J Clin Oncol 2000;18:2545–2552.
39.
Berton-Rigaud D, Viens P, Dieras V, et al: Gemzar (G) and epirubicin (E) in patients (Pts) with metastatic breast cancer (MBC): Final results of a phase I dose finding study. Proc Am Soc Clin Oncol 2000;19:112a.
40.
Murad AM, Guimaraes RC, Arago BC, et al: Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer (MBC) (abstract No. 422). Am Soc Clin Oncol 2000;19:109a.
41.
Colomer R, Llombart A, Lluch A, et al: Biweekly paclitaxel and gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain (abstract No. 373). Proc Am Soc Clin Oncol 2000;19:97a.
42.
Brugnatelli S, Danova M, Tamburo De Bella M, et al: Weekly schedule of gemcitabine (G) plus docetaxel (D) in refractory advanced breast cancer (Bc): A dose-finding study (abstract No. 609I). Proc Am Soc Clin Oncol 2000;19:156a.
43.
Laufman L, Spiridonidis C, Carman L, et al: Second-line chemotherapy with weekly gemcitabine (GEM) and monthly docetaxel (DOC) in patients (Pts) with metastatic breast cancer (MBC): A phase II study (abstract No. 408). Proc Am Soc Clin Oncol 2000;19:106a.
44.
Conte P, Bengala C, Donati S, et al: Gemcitabine, epirubicin, and taxol (GET) followed by high dose chemotherapy (HDCT): High activity with good tolerability in metastatic breast cancer patients (abstract No. 449). Proc Am Soc Clin Oncol 1999;18:118a.
45.
Gennari A, Donati S, Danesi R, et al: The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer. Semin Oncol 2000;27(1 suppl 2):14–19.
46.
Sanchez-Rovira P, Jaen A, Gonzalez-Flores E, et al: Biweekly gemcitabine-adriamycin-paclitaxel combination (GAT) in metastatic breast cancer patients (MBC): Results from a phase II trial (abstract No. 423). Proc Am Soc Clin Oncol 2000;19:109a.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.